CX157
- Generic Name
- CX157
- Drug Type
- Small Molecule
- Unique Ingredient Identifier
- O6L62LZJ0Q
- Background
CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.
- Indication
Anxiety Disorders I,
Depression I
Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers
- First Posted Date
- 2012-07-04
- Last Posted Date
- 2012-07-04
- Lead Sponsor
- CeNeRx BioPharma Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01633437
- Locations
- ๐บ๐ธ
Comprehensive Phase One, Miramar, Florida, United States
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
- Conditions
- Treatment Resistant Depression
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2012-07-10
- Lead Sponsor
- CeNeRx BioPharma Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT01246908
- Locations
- ๐บ๐ธ
Gulfcoast Clinical Research Center, Fort Myers, Florida, United States
๐บ๐ธRichard H. Weisler, M.D. and Associates, Raleigh, North Carolina, United States
๐บ๐ธUniversity of South Florida College of Medicine Psychiatry Center, Tampa, Florida, United States
A Study of CX157 (TriRima) for the Treatment of Depression
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2012-06-27
- Lead Sponsor
- CeNeRx BioPharma Inc.
- Target Recruit Count
- 285
- Registration Number
- NCT00739908
- Locations
- ๐บ๐ธ
Southwestern Research, Inc., Beverly Hills, California, United States
๐บ๐ธCapital Clinical Research Associates, Rockville, Maryland, United States
๐บ๐ธRichard H. Weisler, M.D., P.A., Raleigh, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.